ð¨ The Oncology Patent Cliff Is Here: Is Your Business Prepared to Capitalize on the Opportunity? ð¨
In the rapidly evolving landscape of oncology therapeutics, the expiration of patents—commonly known as the "patent cliff"—poses both a s…
The Patent Cliff Is Approaching—Are You Ready to Seize the Biosimilar First-Mover Advantage?
In the rapidly evolving landscape of biopharmaceuticals, the looming patent cliff is no longer a distant threat—it’s a pressing reality that could redefine mar…
In the high-stakes world of pharmaceuticals, the battle over bioequivalence isn’t just a technical debate—it’s a $200 billion showdown that could redefine how we think about generic drugs and healthcare affordability.
Imagine a landscape where the very…
Prove It’s the Same: The $200 Billion Bioequivalence Fight Reshaping Generic Drugs Read Post »
In the relentless race to bring groundbreaking medicines to market, the path from lab to patient is fraught with hurdles—regulatory, financial, and scientific. Yet, amid these challenges, a strategic pathway emerges that could redefine how pharmaceutic…
In the relentless world of pharmaceutical innovation, the recent enactment of the Inflation Reduction Act (IRA) has sent shockwaves through the industry—yet many stakeholders remain uncertain about what it truly entails and how it will reshape drug pri…
The IRA Price Reset: What It Actually Does to Pharma Pricing, and What Comes Next Read Post »
In the relentless race to innovate, pharmaceutical companies have long relied on a strategic playbook: "evergreening." This tactic involves making minor modifications to existing drugs—new formulations, delivery methods, or slight chemical tw…
When the Patent Wall Crumbles: Secondary Abandonment and the Death of Drug Evergreening Read Post »
In the high-stakes world of pharmaceutical innovation, the race isn’t just about developing groundbreaking drugs—it’s about securing the strategic advantages that turn scientific breakthroughs into profitable realities. Yet, many companies, big and sma…
The Strategic Playbook for Identifying and Securing Drug Patent Licensing Opportunities Read Post »
In the relentless race to develop groundbreaking new drugs, pharmaceutical companies often overlook a game-changing strategy that’s been quietly gaining momentum: drug repurposing. As the industry grapples with soaring R&D costs, lengthy developmen…
No Patents, No Problem: The Untapped Power of Drug Repurposing Read Post »
In the high-stakes world of pharmaceuticals, the race to bring a generic drug to market is more complex—and more strategic—than ever before. While many focus on the primary patent protecting the active pharmaceutical ingredient (API), a deeper layer of…
Beyond the API: Mapping the Secondary Patent Thicket to Forecast Generic Entry Read Post »
Unlocking Hidden Profits: How Specialty Pharmacies Can Double Margins When Generics Hit the Market
In the rapidly evolving landscape of healthcare, specialty pharmacies are often seen as the high-growth segment—driven by complex, high-cost medications …
Double Your Specialty Pharmacy Margins the Day Generics Launch Read Post »
Get new actionable insights and updates from BiotechBlog
